secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2024-09-17T23:59:59+00:00
Accession:  0001437749-24-029380
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences enters consulting agreement with former CEO Remi Barbier
-------------------------------------------------------------------------

- Consulting agreement effective Sep 13, 2024 for one year, with potential one-year extension.
- Barbier to provide support for scientific research and regulatory approval at $100 per hour.
- Confidentiality, non-disparagement, and cooperation terms apply; severance benefits unchanged.
- Barbier may only communicate with CEO or CFO; no contact with other employees without permission.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000143774924029380/0001437749-24-029380-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000143774924029380/sava20240917_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-029380

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer